{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:57:15Z","timestamp":1781204235532,"version":"3.54.1"},"reference-count":139,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.1080\/14728214.2023.2188191","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T09:46:14Z","timestamp":1678441574000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials"],"prefix":"10.1080","volume":"28","author":[{"given":"Thinzar","family":"Min","sequence":"first","affiliation":[{"name":"Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK"},{"name":"Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea Bay University Health Board, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-4964","authenticated-orcid":false,"given":"Stephen C","family":"Bain","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK"},{"name":"Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.34172\/hpp.2020.18"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14225"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6906a3"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12773"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11165"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0770"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.07.022"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.007"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0852-3"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12734"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.06.058"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0428"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1399"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408214"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31506-X"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1177\/014572170202800514"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16107"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13014"},{"key":"cit0021","unstructured":"NDA.Report 1: care Processes and Treatment Targets 2019-20, Full Report. [Cited 2021 Sep 02]. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-diabetes-audit\/report-1-care-processes-and-treatment-targets-2019\u201420."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.02.008"},{"issue":"4","key":"cit0023","first-page":"232","volume":"15","author":"Lepore G","year":"2002","journal-title":"Diabetes Nutr Metab"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.003"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819831695"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-317800"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1071\/HC13114"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2016.02.002"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.11.7.567"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801421"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0090"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5459"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4812"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0039"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39409.507662.94"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014554648"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00573-w"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14148"},{"key":"cit0041","unstructured":"NDA.National Diabetes Insulin Pump Audit: summary Report 2017-18. 2019 2021 Sep 02. https:\/\/www.diabetes.org.uk\/resources-s3\/2019-09\/Insulin_%20Summary_2019_v3.pdf."},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12718"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3833\/pdr.v2005i60.663"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.05.2635"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30280-1"},{"key":"cit0049","unstructured":"EMA.First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. 2019 2021 Sep 01. https:\/\/www.ema.europa.eu\/en\/news\/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes."},{"key":"cit0050","unstructured":"Kemp, Adrian https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html#. 2019"},{"key":"cit0051","unstructured":"EMA.Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus. 2021 Nov 20. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-forxiga-dapagliflozin-5mg-should-no-longer-be-used_en.pdf."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14558"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1321"},{"key":"cit0055","unstructured":"CITR.Collaborative Islet Transplant Registry: ninth Annual Report. https:\/\/citregistry.org\/system\/files\/9AR_Report.pdf. 2016 03\/09\/2021]."},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0364"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134057"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6200.1257"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12100"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061267"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.1116"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0630"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012350"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1068"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2009.02.005"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61309-4"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12611"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0049"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0236"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60931-8"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2753-4"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043980"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"cit0074","first-page":"506","volume":"13","author":"Sims EK","year":"2021","journal-title":"Sci Transl Med"},{"key":"cit0075","unstructured":"Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-riskIndividuals. 2021 Oct 14. https:\/\/investors.proventionbio.com\/2021-07-06-Provention-Bio-Receives-Complete-Response-Letter-CRL-to-Biologics-License-Application-BLA-for-Teplizumab-for-the-Delay-of-Clinical-Type-1-Diabetes-T1D-in-At-risk-Individuals."},{"key":"cit0076","unstructured":"ClincalTrial.gov.Recent-onset type 1 diabetes trial evaluating efficacy and safety of teplizumab (PROTECT).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03875729. 2019 14\/10\/2021]."},{"key":"cit0077","volume-title":"FDA approves first drug that can delay onset of type 1 diabetes","author":"FDA","year":"2022"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1038\/nri1000"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1644-9"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0327"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12361"},{"key":"cit0082","unstructured":"BNF.Rituximab. 2021 Oct 14. https:\/\/bnf.nice.org.uk\/drug\/rituximab.html."},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904452"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810246105"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00139-X"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5857"},{"key":"cit0089","doi-asserted-by":"crossref","unstructured":"BNF.Abatacept. 2021 Oct 14. https:\/\/bnf.nice.org.uk\/drug\/abatacept.html.","DOI":"10.1007\/s40278-021-94467-z"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60886-6"},{"key":"cit0091","unstructured":"ClinicalTrial.gov.CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in RelativesAt-Risk for Type 1. 2013 [Cited 2022 Oct 07."},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2004.40.12.872572"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81722"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006136"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0443"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14770"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1480"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.06.006"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049595"},{"key":"cit0100","unstructured":"ClinicalTrial.gov.Clinical phase II\/III trial of ustekinumab to treat type 1 diabetes (UST1D2).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03941132. 2019 2021 Oct 15."},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2014.02.006"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70065-2"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0557"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0494"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0057"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1103"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0323"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1473"},{"key":"cit0110","unstructured":"ClincalTrial.gov.A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon\u00ae) on Glucose Control in Patients With Type IDiabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01928329. 2013 15\/10\/20201]."},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00436-2"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0691"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0690"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa149"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00019-X"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.01.020"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1390-z"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70115-9"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3778"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0089-4"},{"key":"cit0121","unstructured":"ClinicalTrial.gov.Verapamil SR in Adults WithType 1Diabetes (Ver-A-T1D). 2020 2021 Oct 15. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04545151."},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022474"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2877"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.2337\/db21-192-OR"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059524"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14499"},{"key":"cit0127","unstructured":"ClinicalTrial.gov.A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients WithType 2Diabetes Mellitus. 2018 2021 Nov 16. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03467932."},{"key":"cit0128","unstructured":"ClincalTrial.gov.Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects WithType 2Diabetes Mellitus. 2020 2021 Oct 15. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04606576."},{"key":"cit0129","unstructured":"ClinicalTrial.gov.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects WithType 2Diabetes Mellitus. 2021 Oct 15. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04754334"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32567-3"},{"key":"cit0131","unstructured":"2021 Nov 21. https:\/\/www.jdrf.org\/blog\/2019\/12\/23\/fda-grants-breakthrough-device-status-ilet-bionic-pancreas\/."},{"key":"cit0132","unstructured":"ClincalTrial.gov.The insulin-only bionic pancreas pivotal trial.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04200313. 2019 2021 Nov 24."},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0201.pub"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0200"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2018.01.040"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11463"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.2337\/db18-138-OR"},{"issue":"4","key":"cit0138","first-page":"246","volume":"15","author":"Lombardo F","year":"2002","journal-title":"Diabetes Nutr Metab"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-543X.2006.00155.x"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2023.2188191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T17:54:08Z","timestamp":1702058048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2023.2188191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,2]]}},"alternative-id":["10.1080\/14728214.2023.2188191"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2023.2188191","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}